Trinity Life Sciences is pleased to release our highly anticipated white paper, the Annual State of Global Market Access. This year’s white paper focuses on six key global market access trends and provides payer perspectives on these trends. We explore the consequences of new therapeutic advances and policies aiming to control costs globally and the impacts for pharma manufacturers.

Register for this webinar for a deeper dive into a few trends in the white paper. Join experts from our Evidence, Value, Access & Pricing team, Maximilian Hunt, Partner, Jeff Skaar, Managing Director, and Ismail Ismailoglu, Principal, for an insightful discussion on the hot topics below.

Key Webinar Topics

• Cell & gene therapy expansion and other new drug modalities: The evolving evidence requirements to demonstrate value for these potentially one-time/curative, high-priced therapies
• How the greater availability of real-world evidence is shaping and impacting payer evidence expectations
• The significant increase in market delays and withdrawals due to lower reimbursement opportunity—driven by both policy and cost cutting in U.S. and EU markets—and the implications for manufacturers